The Method to Identify a Biomarker and to Evaluate Its Efficiency for Survival by Using the Joint Model of the Accelerate Failure Time and Longitudinal Data

In this article, we discuss how to identify longitudinal biomarkers in survival analysis under the accelerated failure time model and also discuss the effectiveness of biomarkers under the accelerated failure time model. Two methods proposed by Shcemper et al. are deployed to measure the efficacy of biomarkers. We use simulations to explore how the factors can influence the power of a score test to detect the association of a longitudinal biomarker and the survival time. These factors include the functional form of the random effects from the longitudinal biomarkers, in the different number of individuals, and time points per individual. The simulations are used to explore how the number of individuals, the number of time points per individual influence the effectiveness of the biomarker to predict survival at the given endpoint under the accelerated failure time model. We illustrate our methods using a prothrombin index as a predictor of survival in liver cirrhosis patients.